arrow
U

Ulrike Leiter

Eberhard Karls University of Tubingen
H指数:54
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registry

免疫抑制状态对avelumab治疗晚期默克尔细胞癌真实世界结局的影响:前瞻性MCC-TRIM登记研究的结果

2026-10-100
PRE
S1-Leitlinie Schweißdrüsenkarzinom

S1临床指南:汗腺癌

2026-09-080
OAAI
Beyond the first graft: skin cancer risk and risk stratification in retransplanted solid organ recipients

超越首次移植:再次移植实体器官受者的皮肤癌风险及风险分层

2026-07-150
OAAI
S1 guideline sweat gland carcinoma

S1指南汗腺癌

2026-07-070
OAAI
Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma

未知原发灶黑色素瘤表现出日晒暴露型黑色素瘤的致癌模式和临床病程

2026-05-010
PRE
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma

COMBI-EU:BRAF V600突变黑色素瘤患者辅助达拉非尼联合曲美替尼治疗中不良事件管理及治疗时间的真实世界证据

Cancers
IF4.4
2026-02-180
OA
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

合并症和药物对cSCC免疫治疗疗效的作用: DeCOG多中心分析

2026-01-290
OAAI
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors
2026-01-160
OAAI
Messages for ultraviolet-radiation protection to fair-skinned populations

关于紫外线防护的信息,面向肤色较浅的人群

2025-11-060
OAAI
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial

阿维鲁姆单抗联合西妥昔单抗用于不可切除的III期或IV期皮肤鳞状细胞癌患者的临床活性和安全性结果:来自AliCe这一单臂多中心DeCOG II期试验的数据

2025-09-012
PRE
Outcome of systemic therapy in patients with advanced rare skin cancers: a retrospective multicenter DeCOG study of 209 patients

晚期罕见皮肤癌患者系统性治疗的结局:一项包含209名患者的回顾性多中心DeCOG研究

2025-08-300
PREAI
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG

晚期转移性黑色素瘤的性别特异性生存率——一项DeCOG研究,涉及ADOREG多中心前瞻性皮肤癌登记研究的2032例患者。

2025-07-290
OA
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy

使用Merlin Assay (CP-GEP)对未进行前哨淋巴结活检的930例临床Ⅰ/Ⅱ期黑色素瘤患者独立队列进行风险分层

2025-05-010
OAAI
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus

5-FU 4%乳膏治疗光线性角化症所致局部皮肤反应的管理:一项德尔菲共识

2025-04-300
OA